Modified BrainScope One

K181785 · Brainscope Company, Inc. · PIW · Dec 19, 2018 · Neurology

Device Facts

Record IDK181785
Device NameModified BrainScope One
ApplicantBrainscope Company, Inc.
Product CodePIW · Neurology
Decision DateDec 19, 2018
DecisionSESE
Submission TypeTraditional
Regulation21 CFR 882.1450
Device ClassClass 2
AttributesAI/ML

Intended Use

BrainScope One is a multi-modal, multi-parameter assessment indicated for use as an adjunct to standard clinical practice to aid in the evaluation of patients who have sustained a closed head injury within the past 72 hours (3 days), are between the ages of 18-85 years, have a Glasgow Coma Scale (GCS) score of 13-15 (including patients with concussion / mild traumatic brain injury (mTBI), and are being considered for a head CT. BrainScope One should not be used as a substitute for a CT scan. The BrainScope One Structural Injury Classification ("SIC") uses brain electrical activity to determine the likelihood of structural brain injury visible on head CT. Negative likely corresponds to those with no structural brain injury visible on head CT. Positive likely corresponds to those with a structural brain injury visible on head CT. Equivocal may correspond to structural brain injury visible on head CT or may indicate the need for further observation or evaluation. BrainScope One provides a measure of brain function Index, (BFI)) for the statistical evaluation of the human electroencephalogram (EEG), aiding in the evaluation of head injury as part of a multi-modal, multi-parameter assessment. The BrainScope One device is intended to record, measure, analyze, and display brain electrical activity utilizing the calculation of standard quantitative EEG (QEEG) parameters from frontal locations on a patient's forehead. The BrainScope One calculates and displays raw measures for the following standard QEEG measures in the tive Power, Asymmetry, Coherence and Fractal Dimension. These raw measures are intended to be used for post hoc analysis of EEG signals for interpretation by a qualified user. BrainScope One also provides clinicians with quantitative measures of cognitive performance to aid in the assessment of an individual's level of cognitive function. These measures do not interact with any other device measures, and are stand alone. BrainScope One also stores and displays electronic of standardized clinical assessment tools that should be used in accordance with the assessment tools' general instructions. These tools do not interact with any other device measures, and are stand alone.

Device Story

Portable, point-of-care device; records/analyzes frontal EEG signals via single-use Ag/AgCl electrode headset. Transforms EEG data into Structural Injury Classification (SIC) and Brain Function Index (BFI). Provides quantitative QEEG measures (Absolute/Relative Power, Asymmetry, Coherence, Fractal Dimension), cognitive performance scores, and digital clinical assessment tools. Used by clinicians to aid in head injury evaluation; output supports clinical decision-making regarding head CT necessity. Benefits patient by providing objective, multi-modal assessment data to supplement standard clinical practice.

Clinical Evidence

Clinical performance data from the Ahead 300 (K161068) submission applies. Evidence includes multinomial logistic regression analysis comparing odds ratios of groups with differing functional impairment levels (determined by conventional concussion symptom scales) to a control group, and ANOVAs between groups.

Technological Characteristics

Portable device; Trimble T41 mobile platform (Android OS). Uses single-use Ag/AgCl electrode sensor array (International 10-20 system, frontal positions Fp1, Fp2, Fpz, AFz, F7, F8, A1, A2). ADC resolution 45 nV/bit; 1000 Hz sampling rate (downsampled to 100 Hz). Compliant with IEC 60601-1, IEC 60601-2-26, and ISO 10993 standards.

Indications for Use

Indicated for patients aged 18-85 years who have sustained a closed head injury within the past 72 hours, present with a GCS score of 13-15 (including concussion/mTBI), and are being considered for a head CT. Not a substitute for CT scan.

Regulatory Classification

Identification

A brain injury adjunctive interpretive electroencephalograph assessment aid is a prescription device that uses a patient's electroencephalograph (EEG) to provide an interpretation of the structural condition of the patient's brain in the setting of trauma. A brain injury adjunctive interpretive EEG assessment aid is for use as an adjunct to standard clinical practice only as an assessment aid for a medical condition for which there exists other valid methods of diagnosis.

Special Controls

In combination with the general controls of the FD&C Act, the Ahead 100 is subject to the following special controls:

*Classification.* Class II (special controls). The special controls for this device are:(1) The technical parameters of the device, hardware and software, must be fully characterized and include the following information: (i) Hardware specifications must be provided. Appropriate verification, validation, and hazard analysis must be performed. (ii) Software, including any proprietary algorithm(s) used by the device to arrive at its interpretation of the patient's condition, must be described in detail in the software requirements specification (SRS) and software design specification (SDS). Appropriate software verification, validation, and hazard analysis must be performed. (2) The device parts that contact the patient must be demonstrated to be biocompatible. (3) The device must be designed and tested for electrical safety, electromagnetic compatibility (EMC), thermal, and mechanical safety. (4) Clinical performance testing must demonstrate the accuracy, precision-repeatability and reproducibility, of determining the EEG-based interpretation, including any specified equivocal zones (cutoffs). (5) Clinical performance testing must demonstrate the ability of the device to function as an assessment aid for the medical condition for which the device is indicated. Performance measures must demonstrate device performance characteristics per the intended use in the intended use environment. Performance measurements must include sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) with respect to the study prevalence per the device intended use. (6) The device design must include safeguards to ensure appropriate clinical interpretation of the device output ( *e.g.,* use in appropriate patient population, or for appropriate clinical decision).(7) The labeling and training information must include: (i) A warning that the device is not to be used as a stand-alone diagnostic. (ii) A detailed summary of the clinical performance testing, including any adverse events and complications. (iii) The intended use population and the intended use environment. (iv) Any instructions technicians should convey to patients regarding the collection of EEG data. (v) Information allowing clinicians to gauge clinical risk associated with integrating the EEG interpretive assessment aid into their diagnostic pathway. (vi) Information allowing clinicians to understand how to integrate the device output into their diagnostic pathway when the device is unable to provide a classification or final result.

Predicate Devices

Related Devices

Submission Summary (Full Text)

{0}------------------------------------------------ December 19, 2018 Image /page/0/Picture/1 description: The image shows the logo of the U.S. Food and Drug Administration (FDA). On the left is the Department of Health & Human Services logo. To the right of that is a blue square with the letters FDA in white. To the right of the blue square is the text "U.S. FOOD & DRUG ADMINISTRATION" in blue. BrainScope Company Inc. Michael Singer CEO 4350 East West Hwy, Ste 1050 Bethesda. Maryland 20814 Re: K181785 Trade/Device Name: Modified BrainScope One Regulation Number: 21 CFR 882.1450 Regulation Name: Brain injury adjunctive interpretive electroencephalograph assessment aid Regulatory Class: Class II Product Code: PIW, PKO, OLU Dated: November 28, 2018 Received: November 28, 2018 Dear Michael Singer: We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading. If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR 803) for {1}------------------------------------------------ devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/CombinationProducts/GuidanceRegulatoryInformation/ucm597488.html; good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products, and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm. For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/) and CDRH Learn (http://www.fda.gov/Training/CDRHLearn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (http://www.fda.gov/DICE) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100). Sincerely, Jay R. Gupta -S For Carlos L. Peña, PhD, MS Director Division of Neurological and Physical Medicine Devices Office of Device Evaluation Center for Devices and Radiological Health Enclosure {2}------------------------------------------------ ## Indications for Use 510(k) Number (if known) K181785 Device Name BrainScope One #### Indications for Use (Describe) • BrainScope One is a multi-modal, multi-parameter assessment indicated for use as an adjunct to standard clinical practice to aid in the evaluation of patients who have sustained a closed head injury within the past 72 hours (3 days), are between the ages of 18-85 years, have a Glasgow Coma Scale (GCS) score of 13-15 (including patients with concussion / mild traumatic brain injury (mTBI), and are being considered for a head CT. BrainScope One should not be used as a substitute for a CT scan. · The BrainScope One Structural Injury Classification ("SIC") uses brain electrical activity to determine the likelihood of structural brain injury visible on head CT. Negative likely corresponds to those with no structural brain injury visible on head CT. Positive likely corresponds to those with a structural brain injury visible on head CT. Equivocal may correspond to structural brain injury visible on head CT or may indicate the need for further observation or evaluation. · BrainScope One provides a measure of brain function Index, (BFI)) for the statistical evaluation of the human electroencephalogram (EEG), aiding in the evaluation of head injury as part of a multi-modal, multi-parameter assessment. · The BrainScope One device is intended to record, measure, analyze, and display brain electrical activity utilizing the calculation of standard quantitative EEG (QEEG) parameters from frontal locations on a patient's forehead. The BrainScope One calculates and displays raw measures for the following standard QEEG measures in the tive Power, Asymmetry, Coherence and Fractal Dimension. These raw measures are intended to be used for post hoc analysis of EEG signals for interpretation by a qualified user. · BrainScope One also provides clinicians with quantitative measures of cognitive performance to aid in the assessment of an individual's level of cognitive function. These measures do not interact with any other device measures, and are stand alone. · BrainScope One also stores and displays electronic of standardized clinical assessment tools that should be used in accordance with the assessment tools' general instructions. These tools do not interact with any other device measures, and are stand alone. Type of Use (Select one or both, as applicable) | <div> <span></span> Prescription Use (Part 21 CFR 801 Subpart D) </div> | <div> <span></span> Over-The-Counter Use (21 CFR 801 Subpart C) </div> | |--------------------------------------------------------------------------------|-------------------------------------------------------------------------------| |--------------------------------------------------------------------------------|-------------------------------------------------------------------------------| #### CONTINUE ON A SEPARATE PAGE IF NEEDED. This section applies only to requirements of the Paperwork Reduction Act of 1995. #### *DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.* The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to: > Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov "An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number." {3}------------------------------------------------ Image /page/3/Picture/0 description: The image is a logo for Brainscope. The word "BRAINSCOPE" is written in large, bold, blue letters. There are two horizontal blue lines above and below the word. The "O" in "SCOPE" is stylized to look like a brainwave. There is a registered trademark symbol to the right of the word. 4350 East-West Highway.Suite 1050.Bethesda.Maryland.20814 www.brainscope.com phone 240.752.7680 ## 510(k) SUMMARY1 | Submitter: | BrainScope® Company, Inc.<br>4350 East West Highway Suite #1050<br>Bethesda, MD 20814<br>Phone: (240) 752-7680<br>Fax: (240) 752-7679<br>www.brainscope.com | |-----------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | Contact: | Michael E. Singer, Ph.D.<br>Chief Executive Officer<br>BrainScope Company, Inc.<br>Phone: (240) 752-7677<br>Fax: (240) 752-7679<br>Email: michael.singer@brainscope.com | | Prepared By: | Sabyasachi Roy, Ph.D.<br>Director Regulatory Affairs, Quality Assurance &<br>Compliance | | Device Proprietary Name: | Modified BrainScope One | | Device Common Name: | Brain Injury Adjunctive Interpretive<br>Electroencephalograph Assessment Aid | | Device Classification Name: | Brain Injury Adjunctive Interpretive<br>Electroencephalograph Assessment Aid | | Classification Regulation: | 21 CFR § 882.1450 | | Panel: | Neurology | | Product Codes: | PIW, PKQ, OLU | | Predicate Device: | BrainScope One (K181179) | <sup>1</sup> Prepared in accordance with 21 CFR § 807.87(h) and 21 CFR § 807.92(c). {4}------------------------------------------------ Image /page/4/Picture/0 description: The image shows the word "BRAINSCOPE" in a stylized, blue font. The letters are bold and slightly italicized, with horizontal lines above and below the word. The "O" in "SCOPE" is replaced by a graphic of brainwaves, and a registered trademark symbol is located in the upper right corner of the image. ## Device Description: The Modified BrainScope One is a portable, non-radiation emitting, point of care device intended to provide results and measures to support clinical assessments to aid in the diagnosis of concussion / mild traumatic brain injury (mTBI). It also contains configurable, selectable cognitive performance tests and digitized standard assessment forms. The combination of multi-modal, multi-parameter capabilities is intended to provide a panel of measures to further support the clinical assessment of head injury. BrainScope One provides healthcare professionals with a set of well-developed and researched concussion assessment tools. ## Indications for Use:2 The modified BrainScope One's Indications for Use are as follows: - BrainScope One is a multi-modal, multi-parameter assessment indicated for use . as an adjunct to standard clinical practice to aid in the evaluation of patients who have sustained a closed head injury within the past 72 hours (3 days), are between the ages of 18-85 years, have a Glasgow Coma Scale (GCS) score of 13-15 (including patients with concussion / mild traumatic brain injury (mTBI)), and are being considered for a head CT. BrainScope One should not be used as a substitute for a CT scan. - . The BrainScope One Structural Injury Classification ("SIC") uses brain electrical activity to determine the likelihood of structural brain injury visible on head CT. Negative likely corresponds to those with no structural brain injury visible on head CT. Positive likely corresponds to those with a structural brain injury visible on head CT. Equivocal may correspond to structural brain injury visible on head CT or may indicate the need for further observation or evaluation. - . BrainScope One provides a measure of brain function (EEG Brain Function Index, (BFI)) for the statistical evaluation of the human electroencephalogram (EEG), aiding in the evaluation of head injury as part of a multi-modal, multi-parameter assessment. - The BrainScope One device is intended to record, measure, analyze, and display brain electrical activity utilizing the calculation of standard quantitative EEG (QEEG) parameters from frontal locations on a patient's forehead. The BrainScope One calculates and displays raw measures for the following standard QEEG measures: Absolute and Relative Power, Asymmetry, Coherence and Fractal Dimension. These raw measures are intended to be used for post hoc analysis of Modified BrainScope One 510(k) Summary <sup>2</sup> The differences between the modified BrainScope One and its predicate (BrainScope One) do not alter the intended use of the device nor do they affect the safety and effectiveness of the predicates. The subject and predicate devices have the same overall intended use. {5}------------------------------------------------ Image /page/5/Picture/0 description: The image shows the logo for BrainScope. The logo is in blue and features the word "BRAINSCOPE" in a bold, sans-serif font. There is a horizontal line above and below the word. The letter "O" in "SCOPE" is replaced with a stylized image of a brainwave. There is a registered trademark symbol to the right of the logo. EEG signals for interpretation by a qualified user. - BrainScope One also provides clinicians with quantitative measures of cognitive . performance to aid in the assessment of an individual's level of cognitive function. These measures do not interact with any other device measures, and are stand alone. - . BrainScope One also stores and displays electronic versions of standardized clinical assessment tools that should be used in accordance with the assessment tools' general instructions. These tools do not interact with any other device measures, and are stand alone. {6}------------------------------------------------ Image /page/6/Picture/0 description: The image shows the logo for BrainScope. The logo is in blue and features the word "BRAINSCOPE" in a bold, sans-serif font. There are two horizontal lines under the word. The "C" in "SCOPE" is stylized to look like a brainwave pattern. There is a registered trademark symbol to the right of the word. # Table 1: Indications for Use Comparison to Predicate device | Proposed Device:<br>Modified BrainScope One | Predicate:<br>BrainScope One | Comments | |----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------| | BrainScope One is a multi-modal,<br>multi-parameter assessment indicated<br>for use as an adjunct to standard<br>clinical practice to aid in the<br>evaluation of patients who have<br>sustained a closed head injury within<br>the past 72 hours (3 days), are<br>between the ages of 18-85 years,<br>have a Glasgow Coma Scale (GCS)<br>score of 13-15 (including patients with<br>concussion / mild traumatic brain<br>injury (mTBI)), and are being<br>considered for a head CT. BrainScope<br>One should not be used as a<br>substitute for a CT scan. | BrainScope One is indicated for use<br>as an adjunct to standard clinical<br>practice to aid in the evaluation of<br>patients who are being considered for<br>a head CT, who sustained a closed<br>head injury within 72 hours, present<br>with a Glasgow Coma Scale score<br>(GCS) of 13-15 (including concussion<br>/ mild Traumatic Brain Injury (mTBI)),<br>and are between the ages of 18-85<br>years. BrainScope One should not be<br>used as a substitute for a CT scan. | Expanded to include<br>multi-modal and<br>multi-parameter<br>assessment. | | The BrainScope One Structural Injury<br>Classification ("SIC") uses brain<br>electrical activity to determine the<br>likelihood of structural brain injury<br>visible on head CT. Negative likely<br>corresponds to those with no<br>structural brain injury visible on head<br>CT. Positive likely corresponds to<br>those with a structural brain injury<br>visible on head CT. Equivocal may<br>correspond to structural brain injury<br>visible on head CT or may indicate the<br>need for further observation or<br>evaluation. | A negative BrainScope One<br>Structural Injury Classification using<br>brain electrical activity in patients who<br>sustained a closed head injury within<br>72 hours, likely corresponds to those<br>with no structural brain injury visible<br>on head CT.<br>A positive BrainScope One Structural<br>Injury Classification using brain<br>electrical activity in patients who<br>sustained a closed head injury within<br>72 hours, likely corresponds to those<br>with a structural brain injury visible on<br>head CT.<br>An equivocal BrainScope One<br>Structural Injury Classification using<br>brain electrical activity in patients who<br>sustained a closed head injury within<br>72 hours, may correspond to<br>structural brain injury visible on head<br>CT or may indicate the need for<br>further observation or evaluation. | Equivalent.<br>Combined for clarity. | | BrainScope One provides a measure<br>of brain function (EEG Brain Function<br>Index, (BFI)) for the statistical<br>evaluation of the human<br>electroencephalogram (EEG), aiding<br>in the evaluation of head injury as part<br>of a multi-modal, multi-parameter<br>assessment. | The BrainScope One provides a<br>measure of brain function (EEG Brain<br>Function Index, (BFI)) for the<br>statistical evaluation of the human<br>electroencephalogram (EEG). | Equivalent.<br>Clarification of device<br>capabilities. | | Proposed Device:<br>Modified BrainScope One | Predicate:<br>BrainScope One | Comments | | The BrainScope One device is<br>intended to record, measure, analyze,<br>and display brain electrical activity<br>utilizing the calculation of standard<br>quantitative EEG (QEEG) parameters<br>from frontal locations on a patient's<br>forehead. BrainScope One calculates<br>and displays raw measures for the<br>following standard QEEG measures:<br>Absolute and Relative Power,<br>Asymmetry, Coherence and Fractal<br>Dimension. These raw measures are<br>intended to be used for post hoc<br>analysis of EEG signals for<br>interpretation by a qualified user. | The BrainScope One device is<br>intended to record, measure, analyze,<br>and display brain electrical activity<br>utilizing the calculation of standard<br>quantitative EEG (QEEG) parameters<br>from frontal locations on a patient's<br>forehead. BrainScope One calculates<br>and displays raw measures for the<br>following standard QEEG measures:<br>Absolute and Relative Power,<br>Asymmetry, Coherence and Fractal<br>Dimension. These raw measures are<br>intended to be used for post hoc<br>analysis of EEG signals for<br>interpretation by a qualified user. | Same | | BrainScope One also provides<br>clinicians with quantitative measures<br>of cognitive performance to aid in the<br>assessment of an individual's level of<br>cognitive function. These measures<br>do not interact with any other device<br>measures, and are stand alone. | BrainScope One also provides<br>clinicians with quantitative measures<br>of cognitive performance to aid in the<br>assessment of an individual's level of<br>cognitive function. These measures<br>do not interact with any other device<br>measures, and are stand alone. | Same | | BrainScope One also stores and<br>displays electronic versions of<br>standardized clinical assessment tools<br>that should be used in accordance<br>with the assessment tools' general<br>instructions. These tools do not<br>interact with any other device<br>measures, and are stand alone. | BrainScope One also stores and<br>displays electronic versions of<br>standardized clinical assessment tools<br>that should be used in accordance<br>with the assessment tools' general<br>instructions. These tools do not<br>interact with any other device<br>measures, and are stand alone. | Same | {7}------------------------------------------------ Image /page/7/Picture/0 description: The image is a logo for Brainscope. The logo is in blue and features the word "BRAINSCOPE" in large, bold letters. The "O" in "SCOPE" is stylized with a waveform graphic, and there are horizontal lines above and below the word. There is also a registered trademark symbol to the right of the word. {8}------------------------------------------------ Image /page/8/Picture/0 description: The image shows the BrainScope logo. The logo is in blue and features the word "Brain" in a bold, sans-serif font, with a line above it. The word "Scope" is next to "Brain" and also in blue, with a line above and below it. There is a registered trademark symbol to the right of the word "Scope". #### Comparison of Technological Characteristics with the Predicate Device: The Modified BrainScope One incorporates additional clarification in the Indications for Use statement of its predicate (BrainScope One) to accommodate widely accepted definitions for "concussion" and "mild Traumatic Brain Injury (mTBI)". The core capabilities of the Modified BrainScope One and its fundamental scientific technology remain unaltered compared to the BrainScope One (predicate). The device modifications discussed do not alter the BrainScope One's safety or effectiveness and neither do they change its intended use compared to the predicate. The Modified BrainScope One is substantially equivalent to the predicate BrainScope One. | Topic / Area | Proposed Device:<br>Modified BrainScope<br>One | Predicate:<br>BrainScope One | Comments | |---------------------------------------------|------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------|----------| | Platform | Trimble T41 mobile<br>device, Android OS | Trimble T41 mobile<br>device, Android OS | Same | | Processed<br>EEG<br>Bandwidth | 1kHz sampled data<br>with DC to 300Hz<br>bandwidth and 100Hz<br>sampled data with<br>0.67Hz to 43Hz<br>bandwidth | 1kHz sampled data<br>with DC to 300Hz<br>bandwidth and 100Hz<br>sampled data with<br>0.67Hz to 43Hz<br>bandwidth | Same | | Common<br>Mode<br>Rejection<br>Ratio (CMRR) | < -100 dB (or better) | < -100 dB (or better) | Same | | System Noise<br>Floor | < 0.4 µV in 0.67 Hz to<br>43Hz bandwidth | < 0.4 µV in 0.3 Hz to<br>43Hz bandwidth | Same | | ADC<br>Resolution | 45 nV/bit | 45 nV/bit | Same | | ADC<br>Sampling<br>Rate | 1000 Hz, down<br>sampled to 100 Hz for<br>algorithm processing | 1000 Hz, down<br>sampled to 100 Hz for<br>algorithm processing | Same | | Electrode<br>Placement<br>System | The International 10-20<br>System | The International 10-20<br>System | Same | | Electrode<br>Positions<br>Utilized | Fp1, Fp2, Fpz, AFz, F7,<br>F8, A1, A2 | Fp1, Fp2, Fpz, AFz,<br>F7, F8, A1, A2 | Same | | Electrode<br>Material | Single use Ag/AgCl<br>electrode sensor array<br>headset with solid gel | Single use Ag/AgCl<br>electrode sensor array<br>headset with solid gel | Same | | Real Time<br>EEG Display | Yes | Yes | Same | | Classification | Three tier classification | Three tier classification | Same | #### Table 2. Technological Comparison to Predicate Device Modified BrainScope One 510(k) Summary {9}------------------------------------------------ Image /page/9/Picture/0 description: The image shows the logo for BrainScope. The logo is in blue and features the word "BrainScope" in a stylized font. There are lines above and below the word "BrainScope". There is a registered trademark symbol to the right of the word "BrainScope". | Topic / Area | Proposed Device:<br>Modified BrainScope<br>One | Predicate:<br>BrainScope One | Comments | |-------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------| | Algorithm<br>(Structural<br>Injury<br>Classification) | with results of<br>Negative, Equivocal<br>and Positive outputs. | with results of<br>Negative, Equivocal<br>and Positive outputs. | | | Results<br>Presentation<br>and Reporting<br>Features | Specific raw measures.<br>EEG playback.<br>Structural injury<br>classification and brain<br>function index display.<br>Cognitive performance<br>raw and standard<br>scores including<br>percentiles.<br>Electronic versions of<br>Standard Clinical<br>Assessments. | Specific raw measures.<br>EEG playback.<br>Structural injury<br>classification and brain<br>function index display.<br>Cognitive performance<br>raw and standard<br>scores including<br>percentiles.<br>Electronic versions of<br>Standard Clinical<br>Assessments. | Equivalent. Same<br>primary<br>functionality with<br>minor<br>enhancements<br>made to user<br>interface in<br>modified<br>BrainScope One. | ## Performance Data: The Pre-Specified analyses for the BFI (described in SAR for submission K161068) included a multinomial logistic regression analysis comparing the odds ratio of groups with differing levels of functional impairment, as determined by assessments from conventional concussion symptom scales, to a control group, as well as ANOVAs between these groups. Post-hoc analyses were performed to explore the relationship between conventional concussion symptom scales and the BFI, as well as the relationship between differing levels of functional impairment and the BFI. All clinical performance data from the Ahead 300 (K161068) submission still apply. The Modified BrainScope One device, like its predicate (BrainScope One), is compliant to the following standards: - o IEC 60601-1/A1:2012 Medical Electrical Equipment Part 1: General Requirements for Basic Safety and Essential Performance - IEC 60601-1-2/A1;2007 Medical electrical equipment Section1.2 o Collateral standard: Electromagnetic compatibility - Requirements and tests - IEC 60601-1-6/A1:2013 General Requirements For Basic Safety And o Essential Performance - Collateral Standard: Usability - IEC 60601-2-26:2012 Particular requirements for the basic safety and o essential performance of electroencephalographs - o ANSI/AAMI EC12:2000/(R)2010 Disposable ECG Electrodes Modified BrainScope One 510(k) Summary {10}------------------------------------------------ Image /page/10/Picture/0 description: The image is a logo for BrainScope. The logo is in blue and features the word "BRAINSCOPE" in a stylized font. The letters are bold and have a slightly futuristic look. There are horizontal lines above and below the word "BRAINSCOPE" and a registered trademark symbol is present. - ANSI/AAMI/ISO 10993-1:2009 Biological evaluation of medical devices Part 1: Evaluation and testing within a risk management process - o ANSI/AAMI/ISO 10993-5:2009 Biological Evaluation of Medical Devices Part 5: Tests for In Vitro Cytotoxicity - ANSI/AAMI/ISO 10993-10:2010 Biological evaluation of medical devices o Part 10: Test for irritation and skin sensitization - MIL-STD-810G, Department of Defense Test Method Standard for o Environmental Engineering Considerations and Laboratory Tests - IEC 60529 (2004) Degree of Protection Provided by Enclosures о - ASTM D4169 09, Standard Practice for Performance Testing of Shipping Containers and Systems ## Conclusion: The Modified BrainScope One has the same intended use and same technological characteristics as the predicate device (BrainScope One). The minor differences between the Modified BrainScope One and the predicate (BrainScope One) do not raise new questions of safety and effectiveness. Performance data establish that the modified BrainScope One is as safe and effective as the predicate (BrainScope One). The Modified BrainScope One is substantially equivalent to the predicate (BrainScope One).
Innolitics

Panel 1

/
Sort by
Ready

Predicate graph will load when search results are available.

Embedding visualization will load when search results are available.

PDF viewer will load when search results are available.

Loading panels...

Select an item from the tree

Click any panel, subpart, regulation, product code, or device to see details here.

Section Matches

Results will appear here.

Product Code Matches

Results will appear here.

Special Control Matches

Results will appear here.

Loading collections...